Filing summary
Entity and period: The supplied filing identifies the registrant as DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc. It is a Form 10-Q for the three months ended September 30, 2014, the first quarter of DelMar’s fiscal year ending June 30, 2015. This differs from the request metadata, which specifies Tuhura and “2014 Q1.” The statements are unaudited and reported in U.S. dollars.
Business context
DelMar is an early-stage oncology company developing VAL-083, with its lead program a Phase I/II dose-escalation trial for recurrent, refractory glioblastoma (GBM). The company reported no product revenue and said it did not expect revenue in the near term. VAL-083 was approved for certain indications in China, but the filing states it had not been approved outside China.
Financial performance and liquidity
| Metric | Three months ended September 30, 2014 | Comparable 2013 period or balance-sheet comparison |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $671,627 | $560,235; up 20% |
| General and administrative expense | $445,000 | $741,368; down 40% |
| Net loss | $1,322,361 | Net income of $6,794,232, largely reflecting an $8,094,339 derivative fair-value gain |
| Basic loss per share | $0.04 | Basic income per share of $0.22 |
| Cash used in operating activities | $971,516 | $1,112,180 |
| Cash and cash equivalents | $4,315,746 | $4,759,711 at June 30, 2014 |
| Working capital | $4,161,669 | $4,704,044 at June 30, 2014 |
| Total assets | $4,497,332 | $5,003,910 at June 30, 2014 |
| Total stockholders’ equity | $520,942 | $880,479 at June 30, 2014 |
| Derivative liability | $3,458,662 | $3,329,367 at June 30, 2014 |
Operating cash burn improved year over year. Financing activities provided $527,551 in net proceeds from warrant exercises during the quarter. The company had $335,663 in current accounts payable, accrued liabilities, and related-party payables at September 30; it reported no loan payable after exchanging the Valent loan for preferred shares. The filing does not provide a clear conventional debt total beyond these disclosed balances and liabilities.
Research and development spending increased mainly with clinical and regulatory work, manufacturing preparation, lung-cancer study planning, preclinical research, and patent costs. Reported G&A declined largely because share-based compensation was substantially lower; excluding share-based payments, G&A rose to $417,193 from $369,049.
Material changes and unusual items
- The prior-year quarter’s reported income was driven by a large noncash warrant-liability revaluation gain. In the current quarter, derivative fair-value movements instead contributed a net loss of approximately $201,404, making year-over-year net results difficult to compare as an indicator of operating performance.
- On September 30, DelMar settled a $278,530 related-party loan from Valent Technologies, an entity owned by its Chief Scientific Officer and a director, by issuing 278,530 nonconvertible Series A preferred shares. The shares carry a 3% annual dividend and liquidation priority over common stock.
- The company amended certain Investor Warrants, reducing their exercise price from $0.80 to $0.65 and shortening their exercise period. Exercises generated $527,551 net cash during the quarter; 8,345,751 Investor Warrants remained outstanding at September 30.
- After quarter-end, further Investor Warrant exercises generated $738,626, and the company reported aggregate net proceeds of $1,266,177 from warrant exercises during the quarter and through October 31. It estimated those proceeds, together with related equity reclassifications, would increase net equity by approximately $1,084,644 after September 30.
- After quarter-end, amendments to Dividend Warrants removed redemption and potential cash-settlement provisions; the filing estimates an approximately $825,502 increase in net equity from their revaluation. These are noncash accounting effects, not operating revenue.
Outlook, management commentary, and risks
- Management estimated that existing resources would fund operations through at least the end of March 2016, based on current estimates and warrant-exercise proceeds. This is a forward-looking estimate, not a guarantee.
- The company said advancing VAL-083 into a registration-directed trial would require additional funding. It expected to progress toward such trials in the first half of 2015, subject to completion of dose escalation and discussions with the FDA.
- The FDA had permitted enrollment at additional VAL-083 doses of 50 and 60 mg/m². Enrollment in the 50 mg/m² cohort was ongoing; patients had not yet completed the required post-dose observation period. Management described preliminary signs of stable disease in some patients, but the trial was ongoing and the filing does not establish efficacy.
- Key risks include clinical-trial delays or unfavorable safety results, uncertainty in costs and development timelines, lack of product revenue, and dependence on future financing. If funding is unavailable on acceptable terms, the company may delay, reduce, or discontinue programs or seek an earlier-stage partner.
- Derivative liabilities are Level 3 fair-value estimates based on unobservable inputs and can cause substantial volatility in reported earnings. The company also identified foreign-exchange exposure from Canadian-dollar expenses.
- The company reported no legal proceedings, no off-balance-sheet arrangements, effective disclosure controls, and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer and period: the filing is for DelMar Pharmaceuticals, Inc. and the quarter ended September 30, 2014, not an identified Tuhura filing.
- Review the cash runway assumptions, subsequent warrant proceeds, remaining warrant overhang, and the funding needed for the proposed registration-directed trial.
- Assess the ongoing trial’s enrollment, safety, dose-escalation results, and FDA interactions; distinguish preliminary clinical observations from demonstrated benefit.
- Examine the Series A preferred-stock terms and related-party loan exchange, including the 3% dividend and liquidation preference.
- Understand how warrant fair-value accounting and post-quarter warrant amendments affect reported liabilities, equity, and earnings, separately from cash flows.